Keros Therapeutics Highlights Presentation Of Clinical Trial And Preclinical Study Results From iIs KER-050 Program And Preclinical Data From Its ALK2 Inhibitor Program At 63rd American Society Of Hematology Annual Meeting And Exposition

by | Dec 13, 2021 | Extra Jobs | 0 comments

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.